Recent Updates
Recently added Catalysts
XFOR Positive Sentiment

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

Wednesday, July 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: X4 Pharmaceuticals has appointed Kelly Gold as the new Chief Financial Officer, effective July 1, 2026. This strategic addition to the Board of Directors aims to strengthen the company's leadership as it focuses on improving the lives of individuals with rare hematology diseases. Gold's extensive experience is expected to benefit the company's future direction.
Price reaction · baseline $4.67 (2026-06-30 close) · hit pre-market · 1 other XFOR headline(s) in the window, move may be shared
day 0 close
-12.5%
day 1
-11.6%
day 3 · peak
-15.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of an experienced CFO enhances leadership.
  • Kelly Gold brings strong strategic expertise to the board.
  • Focus on rare hematology diseases aligns with company mission.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+171%
120-day peak, hindsight
Typical move
11.1%
average across 3 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
X4P-001
Phase 2 · WHIM Syndrome

Full Press Release Details

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and

Frequently Asked Questions

Who has been appointed as CFO of X4 Pharmaceuticals?

Kelly Gold has been appointed as the Chief Financial Officer of X4 Pharmaceuticals.

When does Kelly Gold's appointment take effect?

Kelly Gold's appointment as CFO is effective July 1, 2026.

What is X4 Pharmaceuticals focused on?

X4 Pharmaceuticals focuses on improving the lives of people with rare hematology diseases.

What expertise does Kelly Gold bring?

Kelly Gold brings strong strategic expertise to the Board of Directors.

ShareAdd on Google
Tags: XFOR Viatris Investor Conferences Healthcare Kelly Gold CFO Board of Directors hematology diseases
Last updated: Jul 1, 2026

Biotech snapshot

Cash runway
$208M liquidity · $7M/mo burn
~30 mo
Minimal dilution risk
Lead asset
X4P-001Phase 2
WHIM Syndrome →

Catalyst track record

+171%
best trade around XFOR's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for XFOR.

See every catalyst's timing & PoA →